A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

被引:546
作者
Sim, SC
Risinger, C
Dahl, ML
Aklillu, E
Christensen, M
Bertilsson, L
Ingelman-Sundberg, M
机构
[1] Karolinska Inst, Inst Environm Med, Div Mol Toxicol, SE-17177 Stockholm, Sweden
[2] Univ Uppsala Hosp, ARA Life Sci AB, Uppsala, Sweden
[3] Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden
[4] Karolinska Univ Hosp, Karolinska Inst, Div Clin Pharmacol, Dept Lab Med, Huddinge, Sweden
关键词
D O I
10.1016/j.clpt.2005.10.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective: Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP) 2C19 enzyme. A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any genetic background. Methods: The 5'-flanking region of the CYP2C19 gene from subjects with rapid omeprazole metabolism was sequenced, and CYP2C19 phenotype-genotype associations were analyzed in Swedish (n = 107) and Ethiopian (n = 126) extensive metabolizers. The relationship of the metabolic ratio of omeprazole (omeprazole/5-hydroxyomeprazole in plasma 3 hours after drug intake) with the area under the plasma concentration-time curve was used for prediction studies. Electrophoretic mobility shift assays were conducted by use of human nuclear protein extracts. Hepatic reporter vector transfections were carried out in CD1 mice. Results: We identified a novel allele (CYP2C19*17) carrying -806C > T and -3402C > T, with a frequency of 18% in both Swedes and Ethiopians and 4% in Chinese subjects. In Swedes the metabolic ratio of omeprazole was higher in subjects homozygous for CYP2C19*1 (median, 0.50 [interquartile range, 0.37-0.73]) than in those homozygous for CYP2C19*17 (median, 0.25 [interquartile range, 0.15-0.33]) (P = .010). In Ethiopians a similar difference in the S/R-mephenytoin ratio was observed between individuals homozygous for CYP2C19*1 (median, 0.20 [interquartile range, 0.12-0.37]) and those homozygous for CYP2C19*17(median, 0.05 [interquartile range, 0.03-0.06]) (P = .013). Electrophoretic mobility shift assays showed specific binding of human hepatic nuclear proteins to an element carrying -806T but not -806C. Reporter vector experiments showed an increased transcriptional activity of the CYP2C19*17 allele in vivo in mice. Predictions revealed that CYP2C19*17 homozygotes would attain 35% to 40% lower omeprazole area under the plasma concentration-time curve values than subjects homozygous for CYP2C19*1 taking standard doses of omeprazole. Conclusions: CYP2C19*17 is likely to cause therapeutic failures in drug treatment with, for example, proton pump inhibitors and antidepressants.
引用
收藏
页码:103 / 113
页数:11
相关论文
共 45 条
[11]   Sertraline treatment of elderly patients with depression and cognitive impairment [J].
Devanand, DP ;
Pelton, DH ;
Marston, K ;
Camacho, Y ;
Roose, SP ;
Stern, Y ;
Sackeim, HA .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 (02) :123-130
[12]   GATA-4, GATA-5, and GATA-6 activate the rat liver fatty acid binding protein gene in concert with HNF-1α [J].
Divine, JK ;
Staloch, LJ ;
Haveri, H ;
Jacobsen, CM ;
Wilson, DB ;
Heikinheimo, M ;
Simon, TC .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2004, 287 (05) :G1086-G1099
[13]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491
[14]   Pharmacogenomics of proton pump inhibitors [J].
Furuta, T ;
Shirai, N ;
Sugimoto, M ;
Ohashi, K ;
Ishizaki, T .
PHARMACOGENOMICS, 2004, 5 (02) :181-202
[15]   Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole [J].
Furuta, T ;
Shirai, N ;
Watanabe, F ;
Honda, S ;
Takeuchi, K ;
Iida, T ;
Sato, Y ;
Kajimura, M ;
Futami, H ;
Takayanagi, S ;
Yamada, M ;
Ohashi, K ;
Ishizaki, T ;
Hanai, H .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) :453-460
[16]   Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer [J].
Furuta, T ;
Ohashi, K ;
Kamata, T ;
Takashima, M ;
Kosuge, K ;
Kawasaki, T ;
Hanai, H ;
Kubota, T ;
Ishizaki, T ;
Kaneko, E .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) :1027-1030
[17]   CΥP2C19 genotype status and effect of omeprazole on intragastric pH in humans [J].
Furuta, T ;
Ohashi, K ;
Kosuge, K ;
Zhao, XJ ;
Takashima, M ;
Kimura, M ;
Nishimoto, M ;
Hanai, H ;
Kaneko, E ;
Ishizaki, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) :552-561
[18]   Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin [J].
Furuta, T ;
Shirai, N ;
Takashima, M ;
Xiao, F ;
Hanai, H ;
Nakagawa, K ;
Sugimura, H ;
Ohashi, K ;
Ishizaki, T .
PHARMACOGENETICS, 2001, 11 (04) :341-348
[19]   Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19 [J].
Furuta, T ;
Shirai, N ;
Xiao, F ;
Ohashi, K ;
Ishizaki, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (05) :484-492
[20]   Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin [J].
Furuta, T ;
Shirai, N ;
Takashima, M ;
Xiao, F ;
Hanai, H ;
Sugimura, H ;
Ohashi, K ;
Ishizaki, T ;
Kaneko, E .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :158-168